Prática challenge of the management of covid-19 in patients with obesity
Abstract
Obesity is a condition associated with worse outcomes of patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is linked to endocrine and immunological dysfunction, making the patient more vulnerable to the disease caused by the virus. Considering that the pathophysiological mechanisms involved in coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 are still unclear, the search for various drugs for the treatment or prevention of the disease is still in progress. Therefore, it is essential to review the mechanisms of action of drugs on severe COVID-19 and their pharmacological interaction with obesity.
References
-Abduljabbar, T.; Al-Sahaly, F.; Kellesarian, S.V.; Kellesarian, T.V.; Al-Anazi, M.; Al-Khathami, M.; Javed, F.; Vohra, F. Comparison of peri-implant clinical and radiographic inflammatory parameters and whole salivary destructive inflammatory cytokine profile among obese and non-obese men. Cytokine. Vol. 88. 2016. p. 51-56.
-Anjos, L.A. Diagnosis of obesity and determination of nutritional requirements: Challenges for the area of nutrition. Cienc e Saude Coletiva. Vol. 18. Num. 295. 2013.
-Al-Tawfiq, J.A.; Al-Homoud, A.H.; Memish, Z.A. Remdesivir as a possible therapeutic option for the COVID-19. Travel Med Infect Dis. Vol. 34. 2020. 101615.
-Atallah, B.; Mallah, S.I.; AlMahmeed, W. Anticoagulation in COVID-19. Eur Heart J. Vol. 6. 2020. p. 260-261.
-Atri, D.; Siddiqi, H.K.; Lang, J.P.; Nauffal, V.; Morrow, D.A.; Bohula, E.A. COVID-19 for the Cardiologist: Basic Virology, Epidemiology, Cardiac Manifestations, and Potential Therapeutic Strategies. JACC Basic to Transl Sci. Vol. 5. 2020. p. 518-536.
-Badimon, L.; Cubedo, J. Adipose tissue depots and inflammation: Effects on plasticity and residentmesenchymal stem cell function. Cardiovasc Res. Vol. 113. 2017. p. 1064-1073.
-Badimon, L.; Vera, R.H.; Padró, T.; Vilahur, G. Antithrombotic therapy in obesity. Researchgate. Vol. 110. 2013. p. 681-688.
-Beigel, J.H.; Tomashek, J.M.; Dodd, L.E.; Mehta, A.K.; Zingman, B.S.; Kalil, A.C.; Hohmann, E.; Chu, H.Y.; Luetkemeyer, A.; Kline, S.; Lopez de Castilla, D.; Finberg, R.W. Remdesivir for the Treatment of Covid-19. N Engl J Med. Vol. 383. 2020. p. 1813-1826.
-Bollinger, T.; Gies, S.; Naujoks, J.; Feldhoff, L.; Bollinger, A.; Solbach, W.; Rupp J. HIF-1 - and hypoxia-dependent immune responses in human CD4+CD25high T cells and T helper 17 cells. J Leukoc Biol. Vol. 96. 2014. p. 305-312.
-Bucher Della Torre, S.; Courvoisier, D.S.; Saldarriaga, A.; Martin, X.E.; Farpour-Lambert, N.J. Knowledge, attitudes, representations and declared practices of nurses and physicians about obesity in a university hospital: training is essential. Clin Obes. Vol. 8. 2018. p. 122-130.
-Caesar, G. Declaração de pandemia, voos e vistos cancelados: veja números da volta de brasileiros do exterior. 2020. https://g1.globo.com/mundo/noticia/2020/05/02/declaracao-de-pandemia-voos-e-vistos-cancelados-veja-numeros-da-volta-de-brasileiros-do-exterior.ghtml. 2020. accessed 28/07/2020.
-Cao, B.; Wang, Y.; Wen, D.; Liu, W.; Wang, J.; Fan, G.; Ruan, L.; Song, B.; Cai, Y.; Wei, M.; Li, X. A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19. N Engl J Med. Vol. 382. 2020. p. 1787-1799.
-Castoldi, A.; Souza, C.N.; Saraiva Câmara, N.O.; Moraes-Vieira, P.M. The macrophage switch in obesity development. Front Immunol. Vol. 6. 2016.
-Chade J. OMS classifica coronavirus como pandemia e cobra ação dos governos. 2020. https://noticias.uol.com.br/colunas/jamil-chade/2020/03/11/proliferacao-de-coronavirus-leva-oms-a-declarar-pandemia.htm. 2020. accessed 28/07/2020.
-Darvall, K.A.L.; Sam, R.C.; Silverman, S.H.; Bradbury, A.W.; Adam, D.J. Obesity and Thrombosis. Eur J Vasc Endovasc Surg. Vol. 33. 2006. p. 223-233.
-De Jong, A.; Chanques, G.; Jaber, S. Mechanical ventilation in obese ICU patients: From intubation to extubation. Crit Care. Vol. 21. 2017.
-Dietz, W.; Santos-Burgoa, C. Obesity and its Implications for COVID-19 Mortality. Obesity. Vol. 28. Num. 1005. 2020.
-Eichinger, S.; Hron, G.; Bialonczyk, C.; Hirschl, M.; Minar, E.; Wagner, O.; Heinze, G.; Kyrle, P.A. Overweight, Obesity, and the Risk of Recurrent Venous Thromboembolism. Thromb Haemost. Vol. 168. 2008. p. 1678-1683.
-Food and drug administration. FDA Newa Release. FDA Approves First Treatment for COVID-19. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19. 2020. accessed 21/12/2020.
-Galic, S.; Oakhill, J.S.; Steinberg, G.R. Molecular and Cellular Endocrinology Adipose tissue as an endocrine organ. Mol Cell Endocrinol. Vol. 316. 2010. p. 129-139.
-Gbinigie, K.; Frie, K. Should azithromycin be used to treat COVID-19? A rapid review. BJGP Open. Vol. 4. 2020.
-Guo, Y.R.; Cao, D.Q.; Hong, Z.S.; Tan, Y.Y.; Chen, S.D.; Jin, H.J.; Tan, K.S.; Wang, D.Y.; Yan, Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. Vol. 7. 2020.
-Gupta, R.; Misra, A. Contentious issues and evolving concepts in the clinical presentation and management of patients with COVID-19 infectionwith reference to use of therapeutic and other drugs used in Co-morbid diseases (Hypertension, diabetes etc). Diabetes Metab Syndr Clin Res Rev. Vol. 14. 2020. p. 251-254.
-Hajifathalian, K.; Kumar, S.; Newberry, C.; Shah, S.; Fortune, B.; Krisko, T.; Ortiz-Pujols, S.; Zhou, X.K.; Dannenberg, A.J.; Kumar, R.; Sharaiha, R.Z. Obesity is Associated with Worse Outcomes in COVID-19: Analysis of Early Data from New York City. Obesity. Vol. 28. 2020. p.1606-1612.
-Horby, P.A.; Mafham, M.; Linsell, L.; Bell, J.L.; Staplin, N.; Emberson, J.R.; Wiselka, M.; Ustianowski, A. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. Vol. 383. 2020. p. 2030-2040.
-Jia, X.; Yin, C.; Lu, S.; Chen, Y.; Liu, Q.; Bai, J.; Lu, Y. Two Things About COVID-19 Might Need Attention. Preprints. Vol. 2. 2020.
-Jin, Y.; Yang, H.; Ji, W.; Wu, W.; Chen, S.; Zhang, W.; Duan, G. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses. Vol. 12. 2020. p. 372-489.
-John, K.; Marino, J.S.; Sanchez, E.R.; Hinds, T.D. The glucocorticoid receptor: Cause of or cure for obesity?. Am J Physiol - Endocrinol Metab. Vol. 310. 2016. p. 249-257.
-Johnson, A.R.; Justin Milner, J.; Makowski, L. The inflammation highway: metabolism accelerates inflammatory traffic in obesity. Immunol Rev. Vol. 249. 2012. p. 218-238.
-Jorgensen, S.C.J.; Kebriaei, R.; Dresser, L.D. Remdesivir: Review of pharmacology, pre-clinical data and emerging clinical experience for COVID-19. Pharmacotherapy. Vol. 40. 2020. p. 659-671.
-Kalligeros, M.; Shehadeh, F.; Mylona, E.K.; Benitez, G.; Beckwith, C.G.; Chan, P.A.; Mylonakis, E. Association of Obesity with Disease Severity Among Patients with Coronavirus Disease 2019. Obesity. Vol. 28. 2020. p. 1200-1204.
-Kaur, J. A comprehensive review on metabolic syndrome. Cardiol Res Pract. 2014.
-Kruglikov, I.L.; Scherer, P.E.The Role of Adipocytes and Adipocyte-Like Cells in the Severity of COVID-19 Infections. Obesity. Vol. 28. 2020. p. 1187-1190.
-Kumar, R.; Gupta, N.; Kodan, P.; Mittal, A.; Soneja, M.; Wig, N. Battling COVID-19: using old weapons for a new enemy. Trop Dis Travel Med Vaccines. Vol. 6. 2020.
-Lai; C.C.; Shih, T.P.; Ko, W.C.; Tang, H.J.; Hsueh, P.R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. Vol. 55. 2020.
-Li, B.; Yang, J.; Zhao, F.; Zhi, L.; Wang, X.; Liu, L.; Bi, Z.; Zhao, Y. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. Vol. 109. 2020. p. 531-538.
-Li, R.; Wang, H.; Shi, Q.; Wang, N.; Zhang, Z.; Xiong, C.; Liu, J.; Chen, Y.; Jiang, L.; Jiang, Q. Effects of oral florfenicol and azithromycin on gut microbiota and adipogenesis in mice. PLoS One. Vol. 12. 2017.
-Li, Y.N.; Su, Y. Remdesivir attenuates high fat diet (HFD)-induced NAFLD by regulating hepatocyte dyslipidemia and inflammation via the suppression of STING. Biochem Biophys Res Commun. Vol. 526. 2020. p. 381-388.
-Lighter, J.A.; Phillips, M.; Hochman, S.; Sterling, S.; Johnson, D.; Francois, F.; Stachel, A. Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission. Clin Infect Dis. Vol. 71. Num. 15. 2020. p. 896-897.
-Lindahl, S.G.E. Using the prone position could help to combat the development of fast hypoxia in some patients with COVID-19. Acta Paediatr Int J Paediatr. Vol. 109. 2020. p. 1539-1544.
-Luzi, L.; Radaelli, M.G. Influenza and obesity: its odd relationship and the lessons for COVID-19 pandemic. Acta Diabetol. Vol. 57. 2020. p. 759-764.
-Maury, E.; Brichard, S.M. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol. Vol. 314. 2010.
-McSharry, D.; Malhotra, A. Potential influences of obstructive sleep apnea and obesity on COVID-19 severity. J Clin Sleep Med. Vol. 16. 2020. p. 1645.
-Michailidou, Z. Fundamental roles for hypoxia signalling in adipose tissue metabolism and inflammation in obesity. Curr Opin Physiol. Vol. 12. 2019. p. 39-43.
-Morange, P.; Alessi, M. Thrombosis in central obesity and metabolic syndrome : Mechanisms and epidemiology. Thromb Haemost. Vol. 110. 2013. p. 669-680.
-Muscogiuri, G.; Pugliese, G.; Barrea, L.; Savastano, S.; Colao, A. Obesity: The “Achilles heel” for COVID-19?. Metabolism. Vol. 108. 2020.
-Noppe, G.; Van Den Akker, E.L.T.; De Rijke, Y.B.; Koper, J.W.; Jaddoe, V.W.; Van Rossum, E.F.C. Long-term glucocorticoid concentrations as a risk factor for childhood obesity and adverse body-fat distribution. Int J Obes. Vol. 40. 2016. p. 1503-1509.
-Ohashi, K.; Shibata, R.; Murohara, T.; Ouchi, N. Role of anti-inflammatory adipokines in obesity-related diseases. Trends Endocrinol Metab. Vol. 25. 2014. p. 348-355.
-Pan-American Health Organization. Therefore, Dexamethasone Is Curr. Part Treat. Protoc. Patients Infected with SARS-CoV-2 a Moderate to Sev. State. https://www.paho.org/pt/covid19. 2020. accessed 21/12/2020.
-Paredes, S.; Alves, M. Abordagem e tratamento da hiperglicemia induzida por glicocorticóides. Acta Med Port. Vol. 29. 2016. p. 556-563.
-Park, H.S.; Park, J.Y.; Yu, R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-α and IL-6. Diabetes Res Clin Pract. Vol. 69. 2005. p. 29–35.
-Pepperrell, T.; Pilkington, V.; Owen, A.; Wang, J.; Hill, A.M. Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19. J Virus Erad. Vol. 6. 2020. p. 52-60.
-Recovery Collaborative Group. Effect of Dexamethasone in Hospitalized Patients with COVID-19 - Preliminary Report. Oxford Univ. News Release. 2020.
-Rosito, G.A.; Agostino, R.B.D.; Massaro, J.; Lipinska, I.; Mittleman, M.A.; Sutherland, P.; Wilson, P.W.F.; Levy, D.; Muller, J.E.; Tofler, G.H. Association between obesity and a prothrombotic state : the Framingham Offspring Study. Thromb Haemost. Vol. 91. 2004. p. 683-689.
-Ryan, P.M.D.; Caplice, N.M. Is Adipose Tissue a Reservoir for Viral Spread, Immune Activation, and Cytokine Amplification in Coronavirus Disease 2019?. Obesity. Vol. 28. 2020. p. 1191-1194.
-Santos, W.G. Natural history of COVID-19 and current knowledge on treatment therapeutic options. Elsevier Masson SAS. 2020.
-Salazar-Sepúlveda, L.L.; Villarreal-Pérez, J.Z. Impact of diagnosis of overweight and obesity on weight management among hospitalized patients. Obes Res Clin Pract. Vol. 13. 2019. p. 164-167.
-Selim, B.J.; Ramar, K.; Surani, S. Obesity in the intensive care unit: risks and complications. Hosp Pract. Vol. 44. 2016. p. 146-156.
-Selvaraj, V.; Dapaah-afriyie, K.; Finn, A.; Flanigan, T.P. Short-Term Dexamethasone in Sars-CoV-2 Patients. R I Med J. Vol. 103. 2020. p. 39-43.
-Shi, C.; Wang, C.; Wang, H.; Yang, C.; Cai, F.; Zeng, F.; Cheng, F.; Liu, Y. The potential of low molecular weight heparin to mitigate cytokine storm in severe COVID-19 patients : a retrospective clinical study. MedRxiv. Vol. 13. 2020. p. 1087-95.
-Simonnet, A.; Chetboun, M.; Poissy, J.; Raverdy, V.; Noulette, J.; Duhamel, J.; Julien Labreuche, J.; Mathieu, D.; Pattou, F.; Jourdain, M. High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation. Obesity. Vol. 28. 2020. p. 1195-1199.
-Singh, A.K.; Majumdar, S.; Singh, R.; Misra, A. Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician’s perspective. Diabetes Metab Syndr Clin Res Rev. Vol. 14. 2020. p.971-978.
-Skipper, C.P.; Pastick, K.A.; Engen, N.W.; Bangdiwala, A.S.; Abassi, M.; Lofgren, S.M.; Williams, D.A.; Okafor, E.C.; Pullen, M.F. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial. Ann Intern Med. Vol. 173. 2020. p. 623-631.
-Solinas, C.; Perra, L.; Aiello, M.; Migliori, E.; Petrosillo, N. A critical evaluation of glucocorticoids in the treatment of severe COVID-19. Cytokine Growth Factor Rev. Vol. 54. 2020. p. 8-23.
-Spinner, C.D.; Gottlieb, R.L.; Criner, G.D.; Arribas López, J.R.; Cattelan, A.M.; Soriano Viladomiu, A.; Ogbuagu, O.; Malhotra, P.; Mullane, K.M.; Castagna, A.; Chai, L.Y.A. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19: A Randomized Clinical Trial. JAMA - J Am Med Assoc. Vol. 324. 2020. p. 1048-1057.
-Sun, J.K.; Chen, Y.T.; De Fan, X.; Wang, X.Y.; Han, Q.Y.; Liu, Z.W. Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19. Postgrad Med. Vol. 132. 2020. p. 604-613.
-Tamez-Pérez, H.E. Steroid hyperglycemia: Prevalence, early detection and therapeutic recommendations: A narrative review. World J Diabetes. Vol. 6. 2015.
-Tang, N.; Bai, H.; Chen, X.; Gong, J.; Li, D.; Sun, Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. Vol. 18. 2020. p. 1094-1099.
-Tchernof, A.; Després, J.P. Pathophysiology of human visceral obesity: An update. Physiol Rev. Vol. 93. 2019. p. 359-404.
-Thompson-Moore, N.R.; Wanat, M.A.; Putney, D.R.; Liebl, P.H.N.; Chandler, W.L.; 71-Muntz, J.E. Evaluation and Pharmacokinetics of Treatment Dose Enoxaparin in Hospitalized Patients with Morbid Obesity. Clin Appl Thromb. Vol. 21. 2015.513-520.
-Trayhurn, P. Hypoxia and adipose tissue function and dysfunction in obesity. Physiol Rev. Vol. 93. 2013.
-Vandiver, J.W.; Ritz, L.I.; Lalama, J.T. Chemical prophylaxis to prevent venous thromboembolism in morbid obesity: literature review and dosing recommendations. J Thromb Thrombolysis. Vol. 41. 2016. p. 475–481.
-Wang, T.; Milligan, P.E.; Wong, C.A.; Deal, E.N.; Thoelke, M.S. HHS Public Access. Thromb Haemost. Vol. 111. 2015. p. 88-93.
-Wang, Y.; Zhang, D.; Du, G.; Du, R.; Zhao, J.; Jin, Y.; Fu, S.; Gao, L.; Cheng, Z.; Lu, Q.; Hu, Y.; Luo, G.; Wang, K. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. Vol. 395. 2020. p. 1569-1578.
-Weghuber, D.; Mangge, H.; Hochbrugger, E.; Stulnig, T.M. Impact of age and metabolic syndrome on the adipokine profile in childhood and adult obesity. Exp Clin Endocrinol Diabetes. Vol. 122. 2014. p. 363-367.
-Westendorf, A.M.; Skibbe, K.; Adamczyk, A.; Buer, J.; Geffers, R.; Hansen, W.; Pastille, E.; Jendrossek, V. Hypoxia enhances immunosuppression by inhibiting CD4+ Effector T cell function and promoting treg activity. Cell Physiol Biochem. Vol. 41. 2017. p. 1271-1284.
-Williams, E.P.; Mesidor, M.; Winters, K.; Dubbert, P.M.; Wyatt, S.B. Overweight and Obesity: Prevalence, Consequences, and Causes of a Growing Public Health Problem. Curr Obes Rep. Vol 4. 2015. p.363-370.
-Word Health Obesity. Obesity. https://www.who.int/health-topics/obesity#tab=tab_1. 2020. accessed 21/12/2020.
-Word Obesity. About obesity. https://www.worldobesity.org/about/about-obesity. 2020. accessed 28/07/2020.
-World Health Organization. Obesity and overwheight. Obes Overwheight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. 2020. accessed 21/12/2020.
-Wu, C.; Chen, X.; Cai, Y.; Xia, J.; Zhou, X.; Xu, S.; Huang, H.; Zhang, L.; Zhou, X.; Du, C.; Zhang, Y. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. Vol. 180. 2020. p.934-943.
-Xu, C.; Mathews, A.E.; Rodrigues, C.; Eudy, B.J.; Rowe, C.A.; O’Donoughue, A.; Percival, S.S. Aged garlic extract supplementation modifies inflammation and immunity of adults with obesity: A randomized, double-blind, placebo-controlled clinical trial. Clin Nutr ESPEN. Vol. 24. 2018. p. 148-155.
-Yang, Z.; Prinsen, J.K.; Bersell, K.R.; Shen, W.; Yermalitskaya, L.; Sidorova, T.; Luis, P.B.; Hall, L.; Zhang, W.; Du, L.; Milne, G.; Tucker, P.; George, A.L.; Campbell, C.M. Azithromycin Causes a Novel Proarrhythmic Syndrome. Circ Arrhythmia Electrophysiol. Vol. 10. 2017.
-Yates, T.; Razieh, C.; Zaccardi, F.; Davies, M.J.; Khunti, K. Obesity and risk of COVID-19: analysis of UK biobank. Prim Care Diabetes. Vol. 14. 2020. p. 566-567.
-Yuki, K.; Fujiogi, M.; Koutsogiannaki, S. COVID-19 pathophysiology: A review. Clin Immunol. Vol. 215. 2020.
-Zhang, A.J.X.; To, K.K.W.; Li, C.; Lau, C.C.Y.; Poon, V.K.M.; Chan, C.C.S.; Zheng, B.J.; Hung, I.F.N.; Lam, K.S.L.; Xu, A.; Yuen, K.Y. Leptin mediates the pathogenesis of severe 2009 pandemic influenza A(H1N1) infection associated with cytokine dysregulation in mice with diet-induced obesity. J Infect Dis. Vol. 207. 2013. p. 1270-1280.
-Zheng, K.I.; Gao, F.; Wang, X.B.; Sun, Q.F.; Pan, K.H.; Wang, T.Y.; Ma, H.L.; Liu, W.Y.; George, J.; Zheng, M.H. Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. Metabolism. Vol. 101. 2020. p.1-15.
-Zheng, Z.; Peng, F.; Xu B.; Zhao J, Liu H, Peng J, Li Q, Jiang C, Zhou Y, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. Vol. 81. 2020.16-25.
-Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; Guan, L.; Wei, Y. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. Vol. 395. 2020. p. 1054-1062.
-Zou, L.; Dai L.; Zhang, X.; Zhang, Z.; Zhang, Z. Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19. Arch Pharm Res. Vol 43. 2020. p. 765-772.
Copyright (c) 2022 Ana Beatriz Costa, Bruno de Andrade Marquetto, Isabela Rosendo Mendonça, Fabiana Schuelter-Trevisol, Gislaine Tezza Rezin
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish in this journal agree to the following terms:
- Authors retain the copyright and grant the journal the right of first publication, with work simultaneously licensed under the Creative Commons Attribution License BY-NC which allows the sharing of the work with acknowledgment of the authorship of the work and initial publication in this journal.
- Authors are authorized to enter into additional contracts separately for non-exclusive distribution of the version of the work published in this journal (eg, publishing in institutional repository or book chapter), with acknowledgment of authorship and initial publication in this journal.
- Authors are allowed and encouraged to post and distribute their work online (eg, in institutional repositories or on their personal page) at any point before or during the editorial process, as this can bring about productive change as well as increase impact and impact. citation of published work (See The Effect of Free Access).
